Nucleotide mimics and their prodrugs

• US 7,285,658 B2
• Filed: 02/28/2003
• Issued: 10/23/2007
• Est. Priority Date: 02/28/2002
• Status: Expired due to Fees

• Current Assignee: Biota Scientific Management Pty Limited (Vaxart, Inc.)
• Original Assignee: Biota, Inc. (Vaxart, Inc.)
• Inventors: Jin, Yi, Brooks, Jennifer L., Wang, Guangyi, Ariza, Maria Eugenia, Prhavc, Marija, Fagan, Patrick C., Rajwanshi, Vivek K., Bruice, Thomas W., Tucker, Kathleen D., Boyle, Nicholas A., Leeds, Janet M., Cook, Phillip D.
• Primary Examiner(s): Jiang; Shaojia Anna
• Assistant Examiner(s): OLSON, ERIC
• Application Number:
  US10/376,654
• Publication Number:
  US 20040059104A1
• Time in Patent Office: 1,698 Days
• Field of Search: 514/49, 514/51, 514/48
• US Class Current: 536/26.2
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07H 19/04 Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/14 Pyrrolo-pyrimidine radicals
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Claims

1. A compound of Formula (I) which may be a D- or L-nucleotide:

6. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1, a pharmaceutically acceptable salt thereof, optionally in combination with one or more other active ingredients and/or with a pharmaceutically acceptable carrier.

2. A compound of Formula (II) which may be a D- or L-nucleotide:

7. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 2, a pharmaceutically acceptable salt thereof, optionally in combination with one or more other active ingredients and/or with a pharmaceutically acceptable carrier.

3. A compound of Formula (III) which may be a D- or L-nucleotide:

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 3, a pharmaceutically acceptable salt thereof, optionally in combination with one or more other active ingredients and/or with a pharmaceutically acceptable carrier.

4. A compound of Formula (IV) which may be a D- or L-nucleotide:

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 4, a pharmaceutically acceptable salt thereof, optionally in combination with one or more other active ingredients and/or with a pharmaceutically acceptable carrier.

5. A compound of Formula (V) which may be a D- or L-nucleotide:

10. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 5, a pharmaceutically acceptable salt thereof, optionally in combination with one or more other active ingredients and/or with a pharmaceutically acceptable carrier.